DRTS is a broad-spectrum oncology treatment that works against multiple cancer pathways simultaneously, unlike traditional drugs targeting specific protein signatures. The post argues this approach overcomes cancer's resistance mechanisms, though key risks include clinical trial outcomes, regulatory approval, and unproven efficacy versus conventional treatments.